Correlation Copetin Biomarker with Length of Stay Patient Community Acquired Pneumonia

DATE PUBLISHED
October 22, 2019
SECTION
Articles

Abstract

Background: Pneumonia is an inflammation of lung parenchyma caused by virus, bacteria, fungus and parasite. Treatment efficiency at hospital can be evaluate by clinical pathway that is evidence based tool for guiding health that is established internationally since 1980’s. Copeptine biomarker measurement can be used as tool for CAP clinical pathway evaluation.  This study objective is to find out that correlation copeptine biomarker with length of stay patient community acquired pneumonia in Moewardi hospital. Subjects and methods: A mixture of correlative quantitative design between biomarkerof copetine, length of stay and action research. Subjects were taken from the medical record data of community acquired pneumonia patients who were examined for copeptin levels in 2018 followed by action research conducted in two cycles. Results: It was obtained 25 CAP patients examined copeptine levels were then associated with length of stay which found a positive and significant relationship with length of stay with the strength of strong category relationships (r=0,600; p =0,001). From these results it was found that copeptin biomarker levels were able to estimate the length of stay of community acquired pneumonia patients. The result of the action research was that disapproval of copeptine levels was included in the clinical pathway for community acquired  pneumonia patients because it was expensive but there was an improvement in the implementation of clinical pathway evaluation in dr. Moewardi hospital by involving all professional care providers namely doctors, nurses, nutritionist and pharmacist. Conclusion: There is a relationship between copeptine biomarkers and length of stay in community acquired pneumonia patients and there is an improvement in the implementation of CP evaluation in Dr. Moewardi Regional Hospital.

Keywords

Community Acquired pneumonia, Clinical pathway, Copeptin

References

Indonesia, P. dokter paru, 2014. Pneumonia Komunitas Pedoman diagnosis dan penatalaksanaan di Indonesia, 2nd ed. Badan Penerbit Fakultas Kedokteran Universitas Indonesia, Jakarta.

Torres, A., Menéndez, R., Wunderink, R.G., 2016. 33 - Bacterial Pneumonia and Lung Abscess, in: Broaddus, V.C., Mason, R.J., Ernst, J.D., King, T.E., Lazarus, S.C., Murray, J.F., Nadel, J.A., Slutsky, A.S., Gotway, M.B. (Eds.), Murray and Nadel’s Textbook of Respiratory Medicine (Sixth Edition). W.B. Saunders, Philadelphia, pp. 557-582.e22.

https://doi.org/10.1016/B978-1-4557-3383-5.00033-6

Engel, M.F., Postma, D.F., Hulscher, M.E.J.L., Teding van Berkhout, F., Emmelot-Vonk, M.H., Sankatsing, S., Gaillard, C.A.J.M., Bruns, A.H.W., Hoepelman, A.I.M., Oosterheert, J.J., 2013. Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP. Eur. Respir. J. 41, 123–130.

https://doi.org/10.1183/09031936.00029412.

Kolditz, M., Halank, M., Schulte-Hubbert, B., Bergmann, S., Albrecht, S., Höffken, G., 2012. Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumonia. Respir. Med. 106, 1320–1328.

https://doi.org/10.1016/j.rmed.2012.06.008

Yang, H., Li, W., Liu, K., Zhang, J., 2012. Knowledge-based clinical pathway for medical quality improvement. Inf. Syst. Front. 14, 105–117. https://doi.org/10.1007/s10796-011-9307-z

Hipp, R., Abel, E., Weber, R.J., 2016. A Primer on Clinical Pathways. Hosp. Pharm. 51, 416–421. https://doi.org/10.1310/hpj5105-416

hanifah, nurjanah, 2014. memahami penitian tindakan kelas. bandung.

Rotter, T., Kinsman, L., Machotta, A., Zhao, F.-L., van der Weijden, T., Ronellenfitsch, U., Scott, S.D., 2013. Clinical pathways for primary care: effects on professional practice, patient outcomes, and costs. Cochrane Database Syst. Rev.

https://doi.org/10.1002/14651858.CD010706

Curbelo, J., Luquero Bueno, S., Galván-Román, J.M., Ortega-Gómez, M., Rajas, O., Fernández-Jiménez, G., Vega-Piris, L., Rodríguez-Salvanes, F., Arnalich, B., Díaz, A., Costa, R., de la Fuente, H., Lancho, Á., Suárez, C., Ancochea, J., Aspa, J., 2017. Inflammation biomarkers in blood as mortality predictors in community-acquired pneumonia admitted patients: Importance of comparison with neutrophil count percentage or neutrophil-lymphocyte ratio. PLOS ONE 12, e0173947.

https://doi.org/10.1371/journal.pone.0173947

Khan, F., Martin-Loeches, I., 2016. The significance of clinical scores and biological markers in disease severity, mortality prediction, and justifying hospital admissions in patients with community-acquired pneumonia. Community Acquir. Infect. 3, 36. https://doi.org/10.4103/2225-6482.184909

Choo, J., Cheah, J., 2000. Clinical pathways: A direction forward in health care. Aust. Health Rev. 23, 77–87.

Frei, C.R., Bell, A.M., Traugott, K.A., Jaso, T.C., Daniels, K.R., Mortensen, E.M., Restrepo, M.I., Oramasionwu, C.U., Ruiz, A.D., Mylchreest, W.R., Sikirica, V., Raut, M.R., Fisher, A., Schein, J.R., 2011. A clinical pathway for community-acquired pneumonia: an observational cohort study. BMC Infect. Dis. 11, 188. https://doi.org/10.1186/1471-2334-11-188.

Author Details

Harsini .

  • Master of Hospital Management, Postgraduate, Universitas Muhammadiyah Yogyakarta, Yogyakarta, Indonesia, Department of Pulmonology and Respiratory Medicine Medical Faculty of Sebelas Maret University, Indonesia
  • Google Scholar
  • RAJAR Journal

Ikhlas Muhammad Jenie

Arlina Dewi